Immunome acquired worldwide, exclusive rights to a panel of antibodies from Nectin Therapeutics, Bluefin Biomedicine, and from OncoResponse July 30, 2024
Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved PFS in 1L CLL in AMPLIFY Ph 3 trial July 30, 2024
FDA Advisory Committee reviewed Imfinzi for treatment of resectable NSCLC based on AEGEAN Ph 3 trial results July 30, 2024
NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production July 30, 2024
Enrollment of 80mg PK Run-In Cohort in Ph 2 EVANGELINE Trial of (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer Completed July 30, 2024
Positive treatment updates announced from Ph 2 clinical trial, THIO-101, of THIO + cemiplimab (Libtayo®) in heavily pre-treated patients with advanced NSCLC July 30, 2024
CHMP recommends RYBREVANT + chemo for the treatment of adult patients with advanced EGFR-mutated NSCLC after failure of prior therapy July 30, 2024
FDA Accepts BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma July 30, 2024
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to UCART22 product candidate for ALL Treatment July 30, 2024
Regulatory path forward for uproleselan in R/R AML would require an additional clinical trial July 30, 2024
Positive feedback received from FDA on the planned TACTI-004 Ph 3 trial of eftilagimod alfa + KEYTRUDA + chemo for the treatment of 1L NSCLC July 30, 2024
Blenrep (belantamab mafodotin) combinations in multiple myeloma application accepted for review by the EMA July 30, 2024
Ph 2 volasertib program receives “Clearance to Proceed” from the FDA and agreement on the dosing plan for Ph 2 clinical trial July 30, 2024
Positive EU CHMP Opinion for KEYTRUDA + Padcev as 1L Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma July 30, 2024
